Format

Send to

Choose Destination
Pathogens. 2019 Oct 28;8(4). pii: E208. doi: 10.3390/pathogens8040208.

Detection of Second Line Drug Resistance among Drug Resistant Mycobacterium Tuberculosis Isolates in Botswana.

Author information

1
Department of Medical Laboratory Sciences, Faculty of Health Sciences, University of Botswana, Gaborone 0022, Botswana. tuelomogashoa@me.com.
2
Botswana Harvard AIDS Institute Partnership, Gaborone 0000, Botswana. tuelomogashoa@me.com.
3
Botswana Harvard AIDS Institute Partnership, Gaborone 0000, Botswana. pmpmelamu@gmail.com.
4
DST-NRF Centre of Excellence in Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town 7505, South Africa. brigitta@sun.ac.za.
5
DST-NRF Centre of Excellence in Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town 7505, South Africa. 21280606@sun.ac.za.
6
Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel 4002, Switzerland. 21280606@sun.ac.za.
7
Faculty of Science, University of Basel, Basel 4001, Switzerland. 21280606@sun.ac.za.
8
DST-NRF Centre of Excellence in Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town 7505, South Africa. lizma@sun.ac.za.
9
Botswana Harvard AIDS Institute Partnership, Gaborone 0000, Botswana. iketlengt@gmail.com.
10
College of Health Sciences, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban 4041, South Africa. iketlengt@gmail.com.
11
Department of Medical Laboratory Sciences, Faculty of Health Sciences, University of Botswana, Gaborone 0022, Botswana. lmupfumi@gmail.com.
12
Botswana Harvard AIDS Institute Partnership, Gaborone 0000, Botswana. lmupfumi@gmail.com.
13
National Tuberculosis Reference Laboratory, Ministry of Health and Wellness, Gaborone 0000, Botswana. bafanamargaret@gmail.com.
14
Botswana National Tuberculosis Programme, Ministry of Health and Wellness, Gaborone 0000, Botswana. btkgwaadira@gmail.com.
15
Botswana National Tuberculosis Programme, Ministry of Health and Wellness, Gaborone 0000, Botswana. goaba2000@yahoo.com.
16
Botswana National Tuberculosis Programme, Ministry of Health and Wellness, Gaborone 0000, Botswana. ttsholo808@gmail.com.
17
Department of Medical Laboratory Sciences, Faculty of Health Sciences, University of Botswana, Gaborone 0022, Botswana. kasvosvei@ub.ac.bw.
18
Botswana Harvard AIDS Institute Partnership, Gaborone 0000, Botswana. sikhulilemoyo@gmail.com.
19
Department of immunology and infectious diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, MA02115, USA. sikhulilemoyo@gmail.com.
20
DST-NRF Centre of Excellence in Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town 7505, South Africa. rw1@sun.ac.za.
21
Botswana Harvard AIDS Institute Partnership, Gaborone 0000, Botswana. sgaseitsiwe@bhp.org.bw.
22
Department of immunology and infectious diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, MA02115, USA. sgaseitsiwe@bhp.org.bw.

Abstract

The emergence and transmission of multidrug resistant (MDR) and extensively drug resistant (XDR) Mycobacterium tuberculosis (M.tb) strains is a threat to global tuberculosis (TB) control. The early detection of drug resistance is critical for patient management. The aim of this study was to determine the proportion of isolates with additional second-line resistance among rifampicin and isoniazid resistant and MDR-TB isolates. A total of 66 M.tb isolates received at the National Tuberculosis Reference Laboratory between March 2012 and October 2013 with resistance to isoniazid, rifampicin or both were analyzed in this study. The genotypes of the M.tb isolates were determined by spoligotyping and second-line drug susceptibility testing was done using the Hain Genotype MTBDRsl line probe assay version 2.0. The treatment outcomes were defined according to the Botswana national and World Health Organization (WHO) guidelines. Of the 57 isolates analyzed, 33 (58%) were MDR-TB, 4 (7%) were additionally resistant to flouroquinolones and 3 (5%) were resistant to both fluoroquinolones and second-line injectable drugs. The most common fluoroquinolone resistance-conferring mutation detected was gyrA A90V. All XDR-TB cases remained smear or culture positive throughout the treatment. Our study findings indicate the importance of monitoring drug resistant TB cases to ensure rapid detection of second-line drug resistance.

KEYWORDS:

MDR-TB; Mycobacterium tuberculosis; XDR-TB; drug resistance; line probe assay; second-line drugs

PMID:
31661825
DOI:
10.3390/pathogens8040208
Free full text

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI)
Loading ...
Support Center